PTIX (Protagenic Therapeutics) Cyclically Adjusted PB Ratio: (As of Sep. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PTIX Protagenic Therapeutics Inc PTIX
26 GF Score
Price $0.79
! 2 Warning Signs
View Full Analysis

What is Protagenic Therapeutics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Protagenic Therapeutics  (OTCPK:PTIX) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Protagenic Therapeutics Cyclically Adjusted PB Ratio Related Terms


Protagenic Therapeutics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Protagenic Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Protagenic Therapeutics Cyclically Adjusted PB Ratio Chart

Protagenic Therapeutics Annual Data
Trend Dec10 Jun14 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Protagenic Therapeutics Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PTIX vs SCNI, DCOY, BBLG: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Protagenic Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Protagenic Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protagenic Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Protagenic Therapeutics's Cyclically Adjusted PB Ratio falls into.


PTIX
26GF Score
Protagenic Therapeutics Inc PTIX
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Protagenic Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Protagenic Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2025 is calculated as:

For example, Protagenic Therapeutics's adjusted Book Value per Share data for the three months ended in Dec. 2025 was:

Adj_Book=Book Value per Share/CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=-1.237/324.0540*324.0540
=-1.237

Current CPI (Dec. 2025) = 324.0540.

Protagenic Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201506 -1,247.017 238.638 -1,693.363
201603 6,530.201 238.132 8,886.407
201606 1,923.471 241.018 2,586.149
201609 19.808 241.428 26.587
201612 13.524 241.432 18.152
201703 11.883 243.801 15.795
201706 10.242 244.955 13.549
201709 9.184 246.819 12.058
201712 6.654 246.524 8.747
201803 5.266 249.554 6.838
201806 3.055 251.989 3.929
201809 1.763 252.439 2.263
201812 -1.151 251.233 -1.485
201903 -1.975 254.202 -2.518
201906 -2.071 256.143 -2.620
201909 -1.985 256.759 -2.505
201912 -3.462 256.974 -4.366
202003 -3.198 258.115 -4.015
202006 -4.072 257.797 -5.119
202009 -5.517 260.280 -6.869
202012 -6.215 260.474 -7.732
202103 -10.464 264.877 -12.802
202106 37.181 271.696 44.346
202109 34.251 274.310 40.462
202112 32.351 278.802 37.602
202203 28.302 287.504 31.900
202206 26.754 296.311 29.259
202209 23.916 296.808 26.111
202212 22.411 296.797 24.469
202303 20.735 301.836 22.261
202306 17.500 305.109 18.587
202309 13.423 307.789 14.132
202312 11.579 306.746 12.232
202403 6.731 312.332 6.984
202406 2.484 314.175 2.562
202409 2.095 315.301 2.153
202412 1.959 315.605 2.011
202506 -2.150 322.561 -2.160
202509 -2.429 324.800 -2.423
202512 -1.237 324.054 -1.237

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Protagenic Therapeutics Business Description

Address 149 Fifth Avenue, Suite 500, New York, NY, USA, 10010
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
26GF Score

Get the complete analysis for PTIX

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.79
Price